GeneWeave BioSciences is an in vitro clinical diagnostics company based in Los Gatos, Calif., led by CEO Steve Tablak. The company develops diagnostic solutions to advance clinical microbiology and address multi-drug-resistant organisms (MDROs). Its products aim to enable hospitals and physicians to prevent drug-resistant infections, improve antibiotic stewardship and determine optimal antibiotic therapy for critical bacterial infections. GeneWeave raised $12M in funding in a round led by Decheng Capital with participation from Claremont Creek Ventures and XSeed Capital. The company intends to use the proceeds for clinical studies and to commercialize its technology. GeneWeave Biosciences develops a molecular diagnostic platform for the rapid detection of infectious diseases. Its core technology, GeneScout™, is designed to detect life‑threatening pathogens. Led by CEO Steve Tablak, the company is focused on completing development, validation and regulatory clearance of an initial test for the platform. The company intends to use the Series A funding to advance those activities. GeneWeave is based in San Jose, California. In conjunction with the fundraise, Min Cui of Decheng Capital will join the company’s board.

Total raised

$24M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2014